Skip to content
OpenCapital
Get started

Candel Therapeutics, Inc. CADL Q3 2025 earnings

Reported November 13, 2025 · Before market open

EPS-$0.21Miss by $0.04
EPS estimate-$0.17

Next report

Aug 13, 2026 (In 2 weeks)
EPS estimate-$0.22

Financials

Q3 2025

Income statement

See full
Operating income-$13.2M-50.8%
Net income-$11.3M-5.9%
EPS (diluted)-$0.21+36.4%

Balance sheet

See full
Cash & equivalents$87.0M+425%
Total debt$7.2M-38.9%
Total equity$80.1M+625%
Total assets$93.6M+335%

Cash flow

See full
Operating cash flow-$10.2M-55.7%
CapEx$144.0K—
Free cash flow-$10.4M-57.9%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$279.97M+35.2%
Enterprise value$200.21M-1.0%

Returns & leverage

See full
Debt / equity0.1×—
Current ratio8.2×+7.1×

Versus estimates

Diluted EPS

Q1 2026-$0.14Beat by $0.08Q4 2025-$0.54Miss by $0.30
Q3 2025-$0.21Miss by $0.04
Q2 2025-$0.09Beat by $0.08Q1 2025$0.13Beat by $0.37Q4 2024-$0.40Miss by $0.17

Ask the moment Candel Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Candel Therapeutics, Inc. report Q3 2025 earnings?
Candel Therapeutics, Inc. (CADL) reported Q3 2025 earnings on November 13, 2025 before market open.
What were Candel Therapeutics, Inc.'s Q3 2025 revenue and EPS?
Candel Therapeutics, Inc. reported eps of $-0.21 for Q3 2025.
Did Candel Therapeutics, Inc. beat estimates in Q3 2025?
EPS missed the consensus estimate of $-0.17 by $0.04.
How did Candel Therapeutics, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 36.4% from $-0.33.
Where can I find Candel Therapeutics, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-279072) and the 10-Q periodic report (0001193125-25-279086) directly on SEC EDGAR. The filing index links above go to sec.gov.